View all newsletters
Receive our newsletter – data, insights and analysis delivered to you

The OTD Approach

OTD is a CRO focused on oncology, specialised in the anticancer drugs.

OTD is a small and flexible team – our team is composed of MD, PhD or MSc) with a collective experience managing over 60 Phase I-II oncology clinical trials, and fully committed to quality and transparency.

The client benefit is to fully achieve the objectives and in the fastest possible time.

We provide the following services:

  • Protocol Writing & e-CRF Design
  • Regulatory Applications
  • Project Management
  • PV
  • Monitoring
  • Data Management (preferred vendor)
  • Report and Publications writing

OTD unique approach:

  • Our Tactics: OTD’s medical oncologists closely review every patient “hands-on and in real-time”, while there is still time to address eligibility, toxicity and dosing issues.
  • Special resources: Access to leading Principal Investigators and unique patient populations worldwide.

We have a specificity our experience in Phase I First-in Man managing clinically relevant information, analysis and transfer to Sponsor.

Tumour types and therapies

Solid tumours: Bladder, breast, cholangiocarcinoma, colorectal, glioblastoma, head & neck, hepatoma, lung, melanoma, ovary, pancreatic, prostate, renal, sarcomas, stomach, thyroid, and rare tumour types (eg, NMC)

Hematologic malignancies: leukaemia (ALL, AML), Hodgkin’s and non-Hodgkin’s lymphomas, β-hemoglobinopathies (SCA and β-thalassemia major), myeloproliferative disorders

Monotherapy / Combinations: classic cytotoxics, targeted therapeutic agents (small molecules and monoclonal antibodies), hormonal therapies, cell-based therapies, vaccines.

For more information on what OTD can offer you, please fill out the enquiry form attached to this page.

Bromodomain and extra-terminal (BET) proteins are chromatin readers that preferentially affect the transcription of genes with super-enhancers, including oncogenes.
This white paper describes the methods and findings of a dose-escalation, open-label, pharmacokinetic, Phase I study of bromodomain inhibitor OTX015 in patients with lymphoma or...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology